Injective (INJ) Pulls Back to $13.56 Despite Bullish ETF Filing and EVM Upgrade News
Terrill Dicki Jul 30, 2025 12:05
INJ retreats 7.75% to $13.56 after recent highs, but strong fundamentals from Cboe ETF filing and EVM mainnet launch suggest potential buying opportunity near support.
Quick Take
• INJ currently trading at $13.56 (-7.75% in 24h) • INJ RSI at neutral 50.91 level suggesting potential reversal zone • Cboe filed for first staked Injective ETF in the U.S. on July 28th
What's Driving Injective Price Today?
Despite a 7.75% pullback in the past 24 hours, Injective's recent fundamental developments paint a compelling picture for the protocol's future. The Chicago Board Options Exchange (Cboe) filed for the first staked Injective ETF in the United States on July 28th, marking a significant milestone for institutional adoption. This ETF would provide traditional investors access to Injective's staking rewards within a regulated framework, potentially opening the floodgates for institutional capital.
The same day brought another major catalyst with Injective's announcement of Ethernia, an EVM-compatible beta mainnet launch. This upgrade allows Ethereum-based smart contracts to run natively on Injective's network, dramatically expanding developer accessibility and potential network activity. The timing of these announcements coincided with INJ price reaching five-month highs earlier this week.
Recent development activity supports the bullish narrative, with data showing Injective leading Layer-1 blockchains in code commits with over 36,500 tracked. This consistent engineering progress demonstrates the team's commitment to technical advancement despite market volatility.
The current INJ price decline appears to be profit-taking following the 14% surge earlier in the week, rather than a rejection of the fundamental improvements.
INJ Technical Analysis: Mixed Signals at Critical Juncture
Injective technical analysis reveals a complex picture with both bullish and bearish elements competing for control. INJ's RSI currently sits at 50.91, placing it in the neutral zone after cooling off from overbought levels during last week's rally. This RSI positioning often precedes significant directional moves, making the next few trading sessions critical for determining short-term trend direction.
The MACD histogram shows -0.0974, indicating bearish momentum in the near term, while the main MACD line remains positive at 0.6459. This divergence suggests the recent pullback may be a healthy correction within the larger uptrend rather than a trend reversal.
Injective's position within the Bollinger Bands tells an interesting story. The current INJ price of $13.56 sits below the middle band at $13.88, with a %B position of 0.4173. This positioning indicates the recent volatility has pushed INJ into the lower half of its recent trading range, potentially setting up a bounce opportunity.
The Stochastic oscillator shows oversold conditions with %K at 20.06 and %D at 38.39, supporting the case for a potential short-term reversal. Based on Binance spot market data, the daily ATR of $1.15 suggests traders should expect continued volatility in the coming sessions.
Injective Price Levels: Key Support and Resistance
Current Injective support levels present clear risk management opportunities for traders. The immediate support zone sits at $11.85, representing a crucial level that bulls must defend to maintain the overall bullish structure. Below this, stronger support emerges at $8.95, though a move to this level would likely require a broader crypto market correction.
On the upside, INJ resistance becomes apparent at $16.35, which served as the recent high before the current pullback. Breaking above this level would likely target the Bollinger Band upper boundary at $15.82, creating a potential measured move higher.
The INJ/USDT trading pair shows the pivot point at $13.99, just above current levels. A reclaim of this level would suggest the correction has run its course and buyers are stepping in. The 24-hour trading range of $13.48 to $14.93 provides short-term boundaries for day traders looking to capitalize on volatility.
Should You Buy INJ Now? Risk-Reward Analysis
For swing traders, the current INJ price offers an intriguing risk-reward setup. The confluence of oversold technical conditions and positive fundamental catalysts creates a potential buying opportunity near current levels. A position with a stop-loss below $11.85 and initial targets at $15.82 provides approximately 1:2 risk-reward ratio.
Day traders should focus on the $13.99 pivot level reclaim as a signal for short-term bullish continuation. The high volatility environment, evidenced by the $1.15 ATR, creates opportunities for quick profits but requires tight risk management.
Long-term investors may view the current pullback as an accumulation opportunity, particularly given the institutional interest demonstrated by the Cboe ETF filing. The EVM compatibility upgrade represents a fundamental shift that could drive sustained adoption over the coming months.
Conservative traders should wait for a clear break above $14.31 (the 7-day SMA) before entering, as this would confirm the correction has ended and the uptrend is resuming.
Conclusion
Injective's current price action reflects a healthy correction following significant fundamental developments rather than a bearish reversal. The combination of ETF filing, EVM upgrade, and strong development activity provides a solid foundation for future growth. Traders should monitor the $13.99 pivot level closely over the next 24-48 hours, as a reclaim could signal the resumption of the bullish trend toward $16.35 resistance. The neutral INJ RSI and oversold Stochastic readings suggest the correction may be nearing completion, making current levels attractive for risk-tolerant traders.
Image source: Shutterstock.jpg)
